Compare
Rani Therapeutics Holdings, Inc. vs Bio Essence Corp vs Northwest Biotherapeutics Inc vs Cannapharmarx, Inc.
| Latest fiscal year | Rani Therapeutics Holdings, Inc. RANI | Bio Essence Corp BIOE | Northwest Biotherapeutics Inc NWBO | Cannapharmarx, Inc. CPMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.63M | $1.90M | $1.38M | $1.36M |
| Revenue growth (YoY) | +58.9% | +485.8% | -0.3% | +66.1% |
| Gross margin | n/a | 75.3% | n/a | -153.1% |
| Operating margin | n/m | 47.4% | n/m | -245.8% |
| Net margin | n/m | 47.2% | n/m | -817.2% |
| Net income | -$40.95M | $896.2K | -$60.16M | -$11.13M |
| EPS (Diluted) | -$0.45 | n/a | -$0.04 | -$0.02 |
| Operating cash flow | -$18.71M | $1.57M | -$44.76M | -$789.1K |
| Free cash flow | -$18.80M | n/a | -$46.27M | -$794.6K |
| Cash & equivalents | $18.62M | n/a | $3.04M | $1.8K |
| Total assets | $58.62M | $422.5K | $81.29M | $7.02M |
| Total liabilities | $17.11M | $2.50M | $128.86M | $37.17M |
| Shareholders' equity | $33.01M | -$2.07M | -$60.28M | -$30.15M |
| Return on year-end equity | -124.1% | n/a | n/a | n/a |
| Shares outstanding | n/a | 38.01M | 1.56B | 662.50M |
Revenue, most recent five fiscal years
| Fiscal year | Rani Therapeutics Holdings, Inc. | Bio Essence Corp | Northwest Biotherapeutics Inc | Cannapharmarx, Inc. |
|---|---|---|---|---|
| Latest | $1.63M Ended 2025-12-31 | $1.90M Ended 2025-12-31 | $1.38M Ended 2025-12-31 | $1.36M Ended 2025-12-31 |
| 1 year earlier | $1.03M Ended 2024-12-31 | $323.9K Ended 2024-12-31 | $1.38M Ended 2024-12-31 | $820.1K Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $551.5K Ended 2023-12-31 | $1.93M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2022-12-31 | $621.6K Ended 2022-12-31 | $1.68M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | $2.72M Ended 2021-12-31 | $888.0K Ended 2021-12-31 | $1.00M Ended 2021-12-31 | $0 Ended 2021-12-31 |